Analogues of VDAC1-derived peptides
AssigneesB. G. Negev Technologies and Applications Ltd., At Ben-Gurion Unlversity, The National Institute for Biotechnology In the Negev Ltd.
InventorVarda Shoshan-Barmatz
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
Claims9
A method of treating non-alcoholic fatty liver disease (NAFLD) and/or a symptom associated with NAFLD, the method comprises administering to a subject diagnosed to have NAFLD a therapeutically effective amount of a pharmaceutical composition comprising a synthetic peptide, which comprises (i) an analogue of VDAC1-derived peptide, wherein the analogue comprises the amino acid sequence set forth in SEQ ID NO:2 and is completely inverso modified, and (ii) a recognition and/or localization peptide comprising the amino acid sequence set forth in SEQ ID NO:8, thereby treating the non-alcoholic fatty liver disease (NAFLD) and/or the symptom associated thereto.
Dependencies are inferred from the claim text.